Literature DB >> 8548382

Pulmonary pharmacology of WAY-126299A: a dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist.

R E Howell1, L P Jenkins, D A Hartman, W B Gray, D Kubrak, R P Carlson, A F Kreft, D Grimes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8548382     DOI： 10.1007/bf01778316

Source DB:  PubMed          Journal:  Inflamm Res        ISSN： 1023-3830            Impact factor:   4.575


× No keyword cloud information.
  8 in total

Review 1.  Mechanism of airway inflammation in asthma.

Authors:  W W Busse; W F Calhoun; J D Sedgwick
Journal:  Am Rev Respir Dis       Date:  1993-06

2.  Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues.

Authors:  R J Heaslip; D Grimes; J W Berkenkopf; B A Ilsemann; B D Sickels; B M Weichman
Journal:  Eur J Pharmacol       Date:  1993-04-06       Impact factor: 4.432

3.  5-lipoxygenase inhibitory activity of zileuton.

Authors:  G W Carter; P R Young; D H Albert; J Bouska; R Dyer; R L Bell; J B Summers; D W Brooks
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

4.  Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs.

Authors:  R E Howell; B D Sickels; S L Woeppel; L P Jenkins; E B Rubin; B M Weichman
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

5.  The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Authors:  E Israel; P Rubin; J P Kemp; J Grossman; W Pierson; S C Siegel; D Tinkelman; J J Murray; W Busse; A T Segal; J Fish; H B Kaiser; D Ledford; S Wenzel; R Rosenthal; J Cohn; C Lanni; H Pearlman; P Karahalios; J M Drazen
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

6.  The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.

Authors:  P E Malo; R L Bell; T K Shaughnessy; J B Summers; D W Brooks; G W Carter
Journal:  Pulm Pharmacol       Date:  1994-04

7.  WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.

Authors:  D Grimes; R J Sturm; L R Marinari; R P Carlson; J W Berkenkopf; J H Musser; A F Kreft; B M Weichman
Journal:  Eur J Pharmacol       Date:  1993-05-19       Impact factor: 4.432

8.  Rapamycin, a potential disease-modifying antiarthritic drug.

Authors:  R P Carlson; D A Hartman; L A Tomchek; T L Walter; J R Lugay; W Calhoun; S N Sehgal; J Y Chang
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.